NSRX

The company’s focus is on creating Powder-Based Intranasal (PBI) products intended to address acute medical situations and public health threats. This delivery method aims to provide rapid treatment in critical scenarios where immediate intervention is necessary. Nasus Pharma operates entirely within the clinical development phase, meaning it is still testing its product candidates and does not yet have any commercially approved drugs generating revenue.

The company’s development pipeline includes NS002, which is an intranasal epinephrine formulation for use in severe allergic reactions like anaphylaxis. Its other primary candidate is NS001, an intranasal naloxone powder nasal spray being developed for the emergency treatment of opioid overdose. These products target significant unmet needs in emergency care, aiming to offer a stable and easily administered alternative to existing injection-based treatments. Founded in 2019, Nasus Pharma is working to advance these candidates through the regulatory process toward potential future commercialization.